New York TimesThe new moves will probably not fully mollify the critics. For one thing, Mylan is not lowering the list price of EpiPen, just making it easier for consumers to pay for it. So insurance companies, federal health programs like Medicare and Medicaid and …EpiPen maker does damage control with pricing planNew York Post […]
from WordPress http://ift.tt/2bl68RP
via IFTTT
0 comments:
Post a Comment